

# Building on Success – Malaria Control and Elimination

8-9 December 2016, Congress Center Basel, Switzerland

Thursday, December 8

## Day 1

### Welcome and Registration

**08:15** Registration

**08:45** Welcome and Introduction, *Christian Lengeler, Swiss TPH*

### Session 1 – Setting the Scene and Highlighting Successes

*Chair: Marcel Tanner, Swiss TPH*

**09:00** History of Malaria Control and Lessons Learned, *Justin Cohen, Clinton Health Access Initiative, USA*

**09:30** A Quantitative History of Malaria in Maps, *Ewan Cameron, University of Oxford, UK*

**10:00** Where We Stand and Where We Want To Go, *Pedro Alonso, Global Malaria Programme World Health Organization, Switzerland*

**10:30** Coffee Break

### Session 2 – Malaria Vaccines

*Chair: Blaise Genton, Swiss TPH*

**11:00** Challenging the Current Vaccine Pipeline, *Odile Leroy, European Vaccine Initiative, Germany*

**11:30** Vaccine R&D for Infectious Diseases with Epidemic Potential, *Marie-Paule Kieny, World Health Organization, Switzerland*

**12:00** Defining Success for Next Generation Malaria Vaccines, *Melissa Penny, Swiss TPH*

**12:30** Lunch

### Session 3 – Antimalarial Drug Discovery

*Chair: Hans-Peter Beck, Swiss TPH*

**14:00** Mass Production of Gametocytes: Opportunities for Drug and Vaccine Discovery, *Till Voss, Swiss TPH*

**14:30** Global Drug Discovery for Malaria, *Jeremy Burrows, Medicines for Malaria Venture, Switzerland*

**15:00** Drug Discovery at Swiss TPH, *Matthias Rottmann, Swiss TPH*

**15:30** Coffee Break

### Session 4 – Extending the Use of Antimalarials

*Chair: Andrea Bosman, World Health Organization*

**16:00** Seasonal Malaria Chemoprevention, *Badara Cisse, London School of Hygiene and Tropical Medicine, UK*

**16:30** Mass Drug Administration – When Is It Useful? *Kwaku Poku Asante, Kintampo Health Research Centre, Ghana*

**17:00** Changing Malaria Risk for Travellers, *Christoph Hatz, Swiss TPH*

**17:30** Launch of Swiss Malaria Group Photo Contest 2017 and Cocktails

Friday, December 9

## Day 2

---

### Session 5 – Vector Control

Chair: *Pie Müller, Swiss TPH*

09:00 **Vector Control Strategies and Successes**, *Tessa Knox, World Health Organization, Switzerland*

09:30 **Insecticide Resistance: Why It Matters and What We Can Do**, *Mark Hoppé, Syngenta, Switzerland*

10:00 **New Tools and Innovations in Vector Control**, *Sarah Moore, Swiss TPH*

**10:30 Coffee Break**

---

### Session 6 – Surveillance and Health Systems

Chair: *Fabrizio Tediosi, Swiss TPH*

11:00 **Surveillance as an Intervention**, *Marcel Tanner, Swiss TPH*

11:30 **Diagnostics for Malaria Surveillance**, *Ingrid Felger, Swiss TPH*

12:00 **Better Health Systems for Malaria Surveillance and Control**, *Deo Mtasiwa, Private Consultant in Public and Clinical Health, Tanzania*

**12:30 Lunch**

---

### Session 7 – Country Issues, Technical Support and Capacity Building

Chair: *Kaspar Wyss, Swiss TPH*

13:30 **Focus on the Democratic Republic of the Congo**, *Joris Losimba Likwela, National Malaria Control Programme, DR Congo*

14:00 **Focus on Tanzania**, *Renata Mandike, National Malaria Control Programme, Tanzania*

14:30 **Swiss TPH's Support to the Global Malaria Control Effort**, *Helen Prytherch, Swiss TPH*

15:00 **Maintaining Momentum, Achieving Successes**, *Bernard Nahlen, President's Malaria Initiative USAID, USA*

**15:30 Closing Words**, *Jürg Utzinger, Director Swiss TPH*

**15:40 Coffee Break**

---

### Geigy Foundation Award 2016

**16:00 Geigy Foundation Award Ceremony**

**17:30 Cocktails**

## Speaker Profiles

### **Welcome and Introduction, Christian Lengeler, Swiss TPH, Switzerland**

Christian Lengeler is a Unit Head at the Swiss TPH and a Professor of Epidemiology at the University of Basel (Switzerland). For the past 30 years he has worked on the epidemiology and control of tropical diseases, with a strong focus on malaria. He was involved in developing insecticide treated nets (ITNs) as a malaria control tool in the 1990s, and has pioneered many developments in large-scale vector control in sub-Saharan Africa. Since 1999 he has been involved in the establishment and running of the national ITN programme in Tanzania. Since 2014 he also leads a large project aiming at supporting the National Malaria Control Programme in DR Congo. His current research interests are: understanding and improving access to malaria treatment in malaria-endemic countries, improving the quality of basic health care, the introduction of improved diagnostic strategies, the basic science of non-malarial illnesses and the treatment of severe malaria in challenging settings. His focus is on operational research and the process of generating, packaging and disseminating evidence on health interventions for communicable diseases. His unit aims to combine first-class applied research with the implementation of national-scale control programmes in malaria endemic areas. He is also a member of, and chairs a number of expert committees on malaria control.



## Session 1 – Setting the Scene and Highlighting Successes

### **Chair: Marcel Tanner, Swiss TPH, Switzerland**

Marcel Tanner obtained a medical biology PhD from the University of Basel and an MPH from the University of London. He was Director of the Swiss TPH from 1997 to 2015 and continues as Professor of Epidemiology and Medical Parasitology at the University of Basel and at the Federal Institute of Technology. He is President of the Swiss Academy of Sciences. Since 1977, his research ranges from basic research on the cell biology and immunology on malaria, schistosomiasis, trypanosomiasis and filariasis to epidemiological and public health research on risk assessment, vulnerability, health impact and district health planning. His research, teaching and health planning expertise are based on substantial long term experience from working in rural and urban areas in Africa (mainly Tanzania, Chad, Burkina Faso and Côte d'Ivoire) and Asia (China, Thailand, Laos). Besides research the capacity building and North-South partnership was a main interest as reflected in the development of the Ifakara Health Institute in Tanzania. He has published extensively in the many fields (>600 original papers). He also acted and acts as advisor on communicable diseases research and control, health systems strengthening and capacity building in various national and international agencies/bodies and in boards/committees such as e.g. WHO/STAC-TDR, Wellcome Trust, DNDi, NITD, INCLEN-Trust and INDEPTH.



### **Justin Cohen, Clinton Health Access Initiative, USA**

Justin M. Cohen, PhD, is Senior Director of Global Malaria at the Clinton Health Access Initiative. He is an infectious disease epidemiologist, oversees CHAI's operational and technical support to government partners to optimize the impact of national malaria programs, avert the maximum number of deaths possible in the short term, and eliminate malaria sustainably. He leads an 80-person program that is currently assisting over 20 countries across Latin America, sub-Saharan Africa, and Southeast Asia to strengthen surveillance systems, improve data analytics, streamline operations, enhance strategic planning, target interventions, and mobilize financial resources. Justin is a member of the World Health Organization's Malaria Elimination Expert Review Group, the WHO Surveillance, Monitoring, and Evaluation Technical Expert Group, the Malaria Elimination Group, and the Swaziland Malaria Elimination Program's Global Technical Advisory Committee. He serves on the steering committees for the Bill & Melinda Gates Foundation's Malaria Modelling Consortium and Haiti's Malaria Zero Consortium, helped lead assessments of technical, operational, and financial feasibility of achieving and maintaining elimination in Zanzibar and Hispaniola, and is a co-author of the World Health Organization's Elimination Scenario Planning tool as well as over 30 peer-reviewed publications, the majority directly related to the theory and practice of sustainable malaria elimination. Justin earned his doctorate in Epidemiological Science and MPH in International Health from the University of Michigan and studied Molecular, Cellular, and Developmental Biology at Yale University.



### **Ewan Cameron, University of Oxford, UK**

Ewan Cameron, PhD, is Senior Computational Statistician in the Spatial Ecology and Epidemiology Group (SEEG) at the University of Oxford. Ewan researches the geospatial distribution of the global malaria burden within Peter Gething's group. The diverse suite of contemporary statistical techniques he applies to this challenge is informed by his past research in astronomy (University of St Andrews, UK; ETH Zurich, Switzerland) and Bayesian statistics (Queensland University of Technology, Australia).



### **Pedro Alonso, World Health Organization, Switzerland**

Pedro L. Alonso, MD, PhD, is the Director of the WHO Global Malaria Programme in Geneva, Switzerland. The Global Malaria Programme is responsible for the coordination of WHO's global efforts to control and eliminate malaria and sets evidence-based norms, standards, policies and guidelines to support malaria-affected countries around the world. A national of Spain, Dr. Alonso has spent over 30 years in public health. His scientific research work has focused on key determinants of morbidity and mortality in the most vulnerable population groups. He has published over 300 articles in international peer-reviewed journals – primarily on malaria treatment, vaccine trials and preventive therapies – and has served on several national and international committees. He is committed to capacity building of both institutions and individuals, primarily in Africa. Prior to taking up the WHO position, Dr Alonso was Director of the Barcelona Institute for Global Health (ISGlobal), Professor of Global Health at the University of Barcelona, and President of the Governing Board of the Manhica Foundation and the Manhica Health Research Centre in Mozambique.



## Session 2 – Malaria Vaccines

**Chair: Blaise Genton**, Swiss TPH, Switzerland

Blaise Genton is Professor of Tropical and Travel Medicine at the Faculty of Biology and Medicine in Lausanne, Switzerland, and Group Leader in clinical epidemiology and public health at the Swiss TPH. He spent more than 13 years in developing countries working mainly on malaria. Prof. Genton led many clinical trials on malaria vaccines and drugs in Switzerland, Papua New Guinea and Tanzania. His research agenda is focused on the validation of new technologies in the field, promoting evidence-based policy change and evaluating the impact of new interventions when implemented in programmatic conditions.



**Odile Leroy**, European Vaccine Initiative, Germany

Odile Leroy, MD, has been the Executive Director of the European Vaccine Initiative (formerly European Malaria Vaccine Initiative) since 2006, where she manages a portfolio of 16 vaccine development projects, on malaria and other neglected diseases, and currently leads 7 EC/EDCTP/IMI funded projects. She is also coordinator of the infrastructure project TRANSVAC. Dr. Leroy has spent most of her career in vaccine development, as a scientist in Africa for nine years, working in determinants of mortality, and being investigator in phase III vaccine clinical trials, followed by 10 years at Pasteur-Mérieux-Connaught (now Sanofi Pasteur), where she had several positions, including Corporate Clinical Director of airborne vaccines. She joined EMVI in 2002 as Clinical and Regulatory Director, and from 2005 to 2006, headed the European and Developing Countries' Clinical Trial Partnership as Executive Director. She is a trained physician specialising in epidemiology, clinical pharmacology and vaccinology.



**Marie-Paule Kieny**, World Health Organization, Switzerland

Marie-Paule Kieny, PhD, was appointed Assistant Director-General at the World Health Organization in October 2010 and is now leading the Health Systems and Innovation cluster. Prior to this, Dr Kieny directed the WHO Initiative for Vaccine Research since its inception in 2001. Major successes under her leadership were the development and licensing of new vaccines against meningitis and against pandemic influenza in developing countries through pioneering the transfer of technology and know-how. During 2015-2016, Dr Kieny led WHO's Ebola research activities. She is currently in charge of Zika Research & Development (R&D) in WHO as well as of the preparation of an R&D Blueprint to accelerate global research preparedness for future outbreaks. Before coming to WHO, Dr Kieny held top research positions in the public and private sectors of her home country, France. The positions included Assistant Scientific Director of Transgene S.A. from 1981 to 1988, and Director of Research and Head of the Hepatitis C Virus Molecular Virology Group at the Institute of Virology, Institut national de la santé et de la recherche médicale (INSERM) from 1999 to 2000. She received her PhD in Microbiology from the University of Montpellier in 1980, where she was also awarded a University Diploma in Economics, and her Diplôme d'Habilitation à Diriger des Recherches from the University of Strasbourg in 1995.



**Melissa Penny**, Swiss TPH, Switzerland

Melissa Penny, PhD applied mathematics, is a senior member of the malaria modelling group at Swiss TPH. Her work focuses on developing and using mathematical models to provide quantitative evidence to support malaria control and elimination decisions. With a focus on assessing the potential impact of malaria vaccines on transmission and clinical disease, Dr. Penny recently led the multi-institute collaboration that provided evidence to WHO and other stakeholders on the likely public health impact and cost-effectiveness of the malaria vaccine RTS,S.



## Session 3 – Antimalarial Drug Discovery

**Chair: Hans-Peter Beck**, Swiss TPH, Switzerland

Hans-Peter Beck obtained his MSc and PhD in cell biology at the University of Tübingen. After his Post-Doc position at the Wellcome Centre of Molecular Parasitology in Edinburgh/Glasgow where he worked on the bovine parasite *Theileria annulata* he moved as visiting scientist to the Walter and Eliza Hall Institute in Melbourne before he took up the position as group leader in Molecular Parasitology at the Papua New Guinean Institute of Medical Research. During this period he pioneered molecular epidemiology for *Plasmodium falciparum* infections and established a research group working on the cell biology of the parasites. After five years in Papua New Guinea, Dr. Beck moved to the University of Witten-Herdecke, Germany, as group leader and subsequently moved to the Swiss Tropical and Public Health Institute where he holds the position as unit head of a research group and holds a Professorship for Molecular Parasitology at the University of Basel. His research focus is on molecular epidemiology and cell biology of the human malaria parasite *P. falciparum*. His research group in particular focuses on the interaction network of exported proteins of the parasite.



**Till Voss**, Swiss TPH, Switzerland

Till Voss, PhD, is a molecular parasitologist with a special interest in studying malaria epigenetics. He obtained his MSc (1998) and PhD (2002) from the Swiss Tropical and Public Health Institute/University of Basel. He then joined Alan Cowman's laboratory at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, as a postdoctoral fellow where he studied the antigenic variation in malaria parasites and inevitably entered the field of epigenetics. In 2006, Dr. Voss returned to the Swiss TPH with a junior professorship awarded by the Swiss National Science Foundation to establish his own research team. Since then he holds the position of Head of the Malaria Gene Regulation Research Unit and recently also Associate Professor for Molecular Parasitology at the University of Basel. His research focuses on the transcriptional and epigenetic control mechanisms responsible for regulating antigenic variation and sexual commitment of malaria blood stage parasites.



**Jeremy Burrows**, Medicines of Malaria Venture, Switzerland

Jeremy Burrows, PhD, is Vice-President, Head of Drug Discovery at Medicines for Malaria Venture (MMV). Jeremy obtained a MA in chemistry and a DPhil in synthetic organic chemistry at Oxford University (1989-1996). In 1997 he joined ZENECA/ AstraZeneca as a medicinal chemist working in Infection, Cardiovascular and Inflammation research in the UK. In 2005, he was seconded to Sweden in CNS/Pain where he led a section focused on Alzheimer's disease. In 2008, Dr. Burrows joined MMV where he is VP Head of Drug Discovery overseeing a growing portfolio of enabling technology, screening, hit-to-lead and lead optimisation projects both with academic and industrial partners. He sits on the advisory committees for several external drug discovery collaborations and regularly reviews articles and grant proposals within the neglected disease area. In 2013, Dr. Burrows became a Fellow of the Royal Society of Chemistry.



**Matthias Rottmann**, Swiss TPH, Switzerland

Matthias Rottmann, PhD, is a molecular biologist with an interest in drug discovery and development, infectious diseases and parasite biology. He obtained a Diploma in Biology at the University of Saarbrücken (1998) and a PhD 2002 at the University of Stuttgart. Dr. Rottmann joined the Swiss TPH as a postdoctoral researcher in 2003 studying antigenic variation of *Plasmodium falciparum* and was exposed to the fascinating field of drug discovery against malaria. Since 2006 his research at the Swiss TPH is focused on the malaria parasite in cell culture assays and mouse models, with the ultimate aim to discover new antimalarial drugs in a multidisciplinary approach. Dr. Rottmann currently leads malaria drug discovery projects in collaboration with the Wellcome Trust, Novartis, Medicines for Malaria Venture and several external partners. In his 10 years as a scientist in the Parasite Chemotherapy Unit his laboratory contributed to the discovery of novel antimalarial compounds that are currently in clinical development.



## Session 4 – Extending the Use of Antimalarials

**Chair: Andrea Bosman**, World Health Organization, Switzerland

Andrea Bosman, MD, PhD, is the Coordinator of the Prevention, Diagnostics and Treatment Unit of the WHO Global Malaria Programme, generating policy and technical guidance on multiple areas related to diagnostics of malaria and of G6PD deficiency, use of antimalarial medicines used for chemoprevention and treatment at health facilities and at community level.



**Badara Cisse**, London School of Hygiene and Tropical Medicine, UK

Badara Cisse, MD, PhD, obtained his medical degree from the University Cheikh Anta Diop in Dakar Senegal, followed by several trainings in tropical diseases epidemiology in Paris (Paris VI), Brussels (ULB) and London (LSHTM). He obtained a Master's degree in Epidemiology and a PhD in Public Health from the London School of Hygiene and Tropical Medicine (LSHTM), thanks to the Bill and Melinda Gates Malaria Foundation. Over the past decade, Dr. Cisse served as lecturer in Epidemiology at the LSHTM. For most of that time he was on secondment in Senegal to carry out a research agenda on malaria prevention (phases IIb malaria vaccines, seasonal malaria chemo prevention (SMC) and pilot malaria elimination through targeted interventions). Between 2014 and 2015, he also had the opportunity to assist the Malaria Control and Elimination Partnership in Africa as senior technical advisor, in an ambitious malaria elimination campaign. In total, he has successfully run research projects for a grant portfolio of \$12 m., thanks to the Bill and Melinda Gates Foundation, the European and Developing Countries Clinical Trials Partnership, the Wellcome Trust, etc. Without any doubt, his greatest achievement remains the conceptualisation and leadership role for World Health Organization endorsement of SMC.



**Kwaku Poku Asante**, Kintampo, Ghana

Kwaku Poku Asante, MD, MPH, PhD, is a clinical epidemiologist with interest in malaria. He graduated with a BSc. in Medical Sciences, MD degree, Masters in Public Health from the premier University of Ghana, and a PhD from the London School of Hygiene and Tropical Medicine, UK. Dr. Asante has led research projects as a principal investigator in African Countries including Ghana, Burkina Faso, Kenya, and Uganda. He is currently the Chairman of the Clinical Trials Partnership Committee of investigators; a committee of African and other international experts with the aim of conducting clinical research in Africa. He is also the Head of Research at Kintampo Health Research Centre and an Adjunct Lecturer at University of Ghana School of Public Health and at the Mailman School of Public Health at Columbia University in New York. Dr. Asante is a co-recipient of the 2008 Prince of Asturias Foundation Award - an institutional award of the Prince of Asturias Prize for International Cooperation to Kintampo Health Research Centre as Head of Malaria research programs in Kintampo, Ghana.



**Christoph Hatz**, Swiss TPH, Switzerland

Christoph Hatz, MD, is Professor of Tropical and Travel Medicine at the Universities of Basel and Zürich. He has been Chief Medical Officer of the Swiss TPH for 25 years. He is Chairperson of the Expert Committee for Travel Medicine and of TropNet, a European Network for Tropical and Travel Medicine. Dr. Hatz organizes travel and tropical medicine courses in Switzerland, Tanzania and Laos. He is a Member of the Swiss Federal Expert Commission for Vaccination issues and responsible for coordinating malaria recommendations for travellers. His research topics include pre-travel and post-travel health issues, medicine in the tropics and migration medicine.



## Session 5 – Vector Control

**Chair: Pie Müller**, Swiss TPH, Switzerland

Pie Müller, PhD, is a medical entomologist with an interest in the biology of disease vectors, insecticide resistance, entomological surveillance and the development of vector control products. He obtained a Diploma in Physical Anthropology (1997) and a PhD in Sensory Ecology (2002) from the University of Zürich. After having worked for a private consultancy company Dr. Müller joined the Liverpool School of Tropical Medicine, UK, as a postdoctoral researcher in 2004. There he was introduced to the fascinating field of medical entomology and studied the molecular mechanisms of insecticide resistance in malaria vectors. After five years in Liverpool, Dr. Müller moved back to Switzerland where he has been Head of the Vector Control Group and the pesticide testing facility at the Swiss Tropical and Public Health Institute since 2009.



**Tessa Knox**, World Health Organization, Switzerland

Tessa Knox holds a PhD in Tropical Public Health from the University of Queensland, Australia. She joined the WHO Global Malaria Programme in 2014 as Technical Officer within the Entomology and Vector Control (EVC) unit. EVC supports WHO Member States to ensure appropriate and effective vector control for at risk populations, and to address key challenges of insecticide resistance and residual transmission. Dr. Knox established the WHO Global Insecticide Resistance Database and is currently coordinating the development of the WHO Global Vector Control Response.



**Mark Hoppé**, Syngenta, Switzerland

Mark Hoppé is a research entomologist with 25 years' experience at Syngenta. He is currently involved in the development of novel solutions for the control of insects of public health importance. He is also the chair of the Insecticide Resistance Action Committee's (IRAC) Public Health team, co-chairs the VCWG's Insecticide Resistance Management and IRS work stream, and is a fellow of the Royal Entomological Society.



**Sarah Moore**, Swiss TPH, Tanzania

Sarah Moore, PhD, is a vector ecologist specializing in the chemical ecology and control of *Anopheles* mosquitoes with a focus on new and existing methods of repelling mosquitoes to protect individuals, households and communities. This includes repellents, repellent treated clothing and odour baited traps. Since arriving in Africa and witnessing the elegance of bed nets as a malaria control tool in this setting, she branched out into evaluation of new indoor vector control tools including bed nets and insecticides used for indoor spraying with new combinations of active ingredients or longer lasting formulations. As her knowledge of vector control deepened, she added epidemiological evaluations of vector control tools to her research portfolio. Her work is dedicated to accurately measuring the efficacy of vector control tools using appropriate experimental design and data analysis in an open and collaborative way, and supporting others to build their own capacity to be able to do the same. In this way she hopes to assist the global malaria control community to respond to the ever-shifting vector control environment to achieve malaria eradication in a timely and cost effective manner. Dr. Moore is based full time at Ifakara Health Institute in Tanzania ([www.ihl.or.tz/](http://www.ihl.or.tz/)).



## Session 6 – Surveillance and Health Systems

**Chair: Fabrizio Tediosi**, Swiss TPH, Switzerland

Fabrizio Tediosi, BSc, MSc, PhD is an economist specialized in public health and health systems and policy analysis. His current research interests focus on a) how to strengthen institutions to promote good governance of health systems and translating evidence to policy; b) developing and applying methods to evaluate and validate health interventions for delivering them at adequate levels of effective coverage. He is also Adjunct Professor and associate researcher at Bocconi University, Milan, Italy.



**Marcel Tanner**, Swiss TPH, Switzerland...See above

**Ingrid Felger**, Swiss TPH, Switzerland

Ingrid Felger, PhD, has served as Head of the Molecular Diagnostics unit at the Swiss TPH since 1996, where she leads the development of new tests for individual diagnosis and population studies. Her major research activities are on molecular epidemiology of *Plasmodium vivax* and *P. falciparum*. Molecular parameters are developed to describe parasite population genetics, transmission dynamics and survival of individual parasite clones in the host. Dr Felger's field based research is conducted within worldwide collaborations in Africa, Asia, Oceania, and Brazil. She previously worked at the Papua New Guinea Institute of Medical Research (1991-1994).



**Deo M. Mtasiwa**, Private Consultant in Public and Clinical Health, Tanzania

Deo M. Mtasiwa, MD, PhD, is a private consultant in the field of Public and Clinical Health. He was the Deputy Permanent Secretary – President's office – Regional Administration and Local Government from January to June 2016, assisting the Permanent Secretary on health and issues for other sectors of regional and local government interest. Prior to that, Dr. Mtasiwa was a Deputy Permanent Secretary, responsible for Health Sectoral Issues, under the Prime Minister's office, Regional Administration and Local Government, from August 2013 to December 2015, and the Chief Medical Officer, at the Ministry of Health, from March, 2007 to July, 2013. He worked as a District and Regional Medical Officer for Ilala District and Dar es Salaam Region, respectively, from July 1980-March 2007. Dr. Mtasiwa graduated in Medicine in 1979 at the University of Dar es Salaam and PhD in Internal Medicine at Hiroshima University in Japan (October 1985 – October 1990). While in these leadership positions, he participated in implementing various innovative public and clinical health programs, research activities and produced several publications.



## Session 7 – Country Issues, Technical Support and Capacity Building

**Chair: Kaspar Wyss**, Swiss TPH, Switzerland

Kaspar Wyss, PhD, is a Public Health Specialist, Professor and Head of Department of the Swiss Centre for International Health, Swiss Tropical and Public Health Institute. He has strong management and leadership experience and is in charge of a team of over 50 staff in Basel focusing on health systems development primarily in low- and middle income countries. His activities relate to both research and health system monitoring and performance assessment, with a specific interest in the role and importance of human resources for health. Prof. Wyss directs a number of research and implementation projects in Africa, Eastern Europe, and Asia and has extensive consultancy experiences for a broad range of clients such as the World Bank, the Swiss Agency for Development and Cooperation, the German GIZ and KfW. He teaches courses on health systems for the University of Basel and other universities, and supervises several PhD and MSc students.



**Joris Losimba Likwela**, National Malaria Control Programme, DR Congo

Joris Losimba Likwela, MD, MPH, PhD, has been Country Director of the National Malaria Control Programme in DR Congo since April 2013. In February 2013 Dr. Likwela was appointed Associate Professor in the Department of Public Health of the Faculty of Medicine of the University of Kisangani. From 2004 to 2013, he was Provincial Coordinator of the Malaria Control Program for the Eastern Province. From 2000 to 2002, before joining the University of Kisangani as assistant in the paediatric department of the University Clinics, Dr. Likwela was General practitioner in the city of Kisangani, then Director of the Hospital of Bugarula in the north of Idjwi Island in the Province of South Kivu. In 2004, he coordinated the fight against malaria in the country's largest region. Dr. Likwela obtained a Master's degree in Public Health from Université Libre de Bruxelles and Université Catholique de Louvain in 2006. From 2007 to 2012 he pursued a PhD in Public Health specializing in the epidemiology of malaria in the DRC. His focus was on intermittent preventive treatment in pregnant women in the context of the emergence of *Plasmodium falciparum* resistance to sulfadoxine-pyrimethamine, the adherence of healthcare providers and patients to malaria treatment, and clinical and evolutionary profile of severe malaria in children.



**Renata Mandike**, National Malaria Control Programme, Tanzania

Renata Mandike, PhD, is a Medical Epidemiologist and Deputy Manager for the National Malaria Control Programme in Tanzania and Heads the Surveillance, Monitoring and Evaluation unit. She has been part of the engineering team to roll out malaria control intervention and to roll back malaria in Tanzania since the inception of Roll Back Malaria Partnership in early 2000's. Her presentation today on "Achievements and Challenges" for malaria control in Tanzania, comes from her vast experience gained over the years.



**Helen Prytherch**, Swiss TPH, Switzerland

Helen Prytherch, PhD, is a Sociologist, Registered Nurse and Public Health Specialist. She has 17 years' work experience gained at all levels of the health system across a variety of countries in Asia, Latin America and sub-Saharan Africa. Her main areas of expertise comprise health system strengthening, health financing, quality management and human resources for health. She has a particular interest in interdisciplinary and multisectoral approaches to health issues, with a focus on HIV/AIDS and malaria. Dr. Prytherch leads the Health System Strengthening Unit at the Swiss Centre for International Health – the consulting department of Swiss TPH.



**Bernard Nahlen**, President's Malaria Initiative USAID, USA

Bernard Nahlen, MD, has been Deputy Coordinator of the U.S. President's Malaria Initiative since 2007. He completed his residency in Family Practice at the University of California, San Francisco before joining the U.S. Center for Disease Control and Prevention (HHS/CDC) in 1986 as an Epidemic Intelligence Service Officer assigned to the Malaria Branch. In 1989, he completed a second residency in Preventive Medicine and later served as Deputy Director of the Los Angeles County AIDS Epidemiology Program. Dr. Nahlen's commitment to malaria prevention and control subsequently took him to Kenya in 1992 as Director of the CDC field research station in collaboration with the Kenya Medical Research Institute (KEMRI). In 2000, he served as Senior Technical Advisor to the WHO Malaria Programme. At WHO, he led the Monitoring and Evaluation team as well as the Malaria in Pregnancy team. From 2005-2006, Dr. Nahlen served as a Senior Advisor in the Performance Evaluation and Policy unit of the Global Fund to Fight AIDS, Tuberculosis and Malaria.



**Closing Words: Jürg Utzinger**, Swiss TPH, Switzerland

Jürg Utzinger, Director of the Swiss TPH, is trained in environmental sciences (MSc) and epidemiology (PhD) with several years of postdoctoral research in demography and epidemiology at Princeton University. Before his appointment as Director of the Swiss TPH, Dr. Utzinger headed the Ecosystem Health Sciences unit at the Department of Epidemiology and Public Health, Swiss TPH. The group pursues a wide variety of epidemiological research, including health impact assessment of large foot-print development projects in the tropics and risk profiling of parasitic diseases, and they have ongoing collaborative projects in Côte d'Ivoire, China and elsewhere in Africa and Asia. Together with colleagues in Côte d'Ivoire, Dr. Utzinger established the first health and demographic surveillance system in the Taabo area, which serves as a platform for monitoring and surveillance of health and well-being of 40,000 mainly rural dwellers. Dr. Utzinger is also Professor of Epidemiology at the University of Basel focusing on epidemiology, diagnosis and integrated control of neglected tropical diseases and malaria. He has extensively published in peer-reviewed literature, edited several special thematic journal issues and wrote numerous book chapters. He is founding deputy editor of PLoS Neglected Tropical Diseases and acts on the editorial boards of Acta Tropica, Geospatial Health and Parasites & Vectors.



## Symposia 2017

### Evidence Meets Decisions Makers – Better Use of Evidence for Better Health

6 April, Parterre Rialto, Basel, Switzerland



The Swiss TPH Spring Symposium 2017 invites public health policy makers, statisticians, global health specialists and students to review and discuss the current evidence on how the use of data and information by decision makers can be improved in the health sector. Topics will include:

- How decision makers make decisions
- What works in promoting the use of evidence
- Teaching and Training evidence
- Technology: from paper to electronics
- Methods: statistical modeling, systematic reviews and guidance development

### Clinical Research in Resource Limited Settings – Mission Impossible or Role Model for Future Drug Development?

June 28, Zentrum für Lehre und Forschung, University Hospital Basel, Switzerland



The Swiss TPH Summer Symposium 2017 invites clinical researchers, drug development specialists and students to review and discuss future approaches to drug development. Topics will include:

- Cost explosion of drug development
- Impact of GCP-guideline amendment 2016
- Conducting sponsor-investigator trials in Switzerland
- Clinical trials in low resource settings
- The Biotech approach to clinical development
- The Pharma view on clinical development
- Alternative business models and partnerships
- What we can learn from R&D in low resource settings

### Helminth Infection - from Transmission to Control

7-8 December, Parterre Rialto, Basel, Switzerland



The Swiss TPH Winter Symposium 2017 invites medical parasitologists, infection biologists, epidemiologists and public health specialists and students to review and discuss progress in research, control, elimination and eradication of helminth infections. Topics will include:

- Health impact versus health benefits of helminth infections
- Towards better treatment options for helminth infections
- Latest diagnostic developments
- From morbidity control to elimination and eradication